Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10114327 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL10114387 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL278192 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL13144983 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL13204166 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL11936567 | 1.00 | MAPT (0.50) | MAPTNPY5RALDH1A1EPHX2NAMPT | |
| SCHEMBL13204366 | 0.91 | MAPT (0.46) | MAPTNPY5RALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL10114837 | 0.91 | MAPT (0.46) | MAPTNPY5RALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL14424363 | 0.91 | MAPT (0.46) | MAPTNPY5RALDH1A1EPHX2SMN1; SMN2 | |
| SCHEMBL10134488 | 0.91 | MAPT (0.46) | MAPTNPY5RALDH1A1EPHX2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8115027-B2 | NPY Y5 antagonist | SHIONOGI & CO., LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20110060145-A1 | PROCESS FOR PRODUCTION OF COMPOUND HAVING ANTAGONISTIC ACTIVITY ON NPYY5 RECEPTOR, AND USEFUL CRYSTAL | SHIONOGI & CO., LTD. (JP) | 2011-03-10 | — | — | US | disclosed |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2011-02-17 | — | — | US | disclosed |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | KAWANISHI YASUYUKI | 2010-11-18 | — | — | US | disclosed |
| US-7795471-B2 | Process for trans-4-amino-1-cyclohexanecarboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-7781461-B2 | NPY Y5 antagonist | KAWANISHI YASUYUKI | 2010-08-24 | — | — | US | disclosed |
| US-20090221817-A1 | Triethylamine was added dropwise to a solution of 2-methylpropane-2-sulfinyl chloride and methyl trans-4-amino-1-cyclohexane carboxylate p-toluenesulfonate in tetrahydrofuran solvent to obtain Methyl trans-4-(2-methylpropane-2-sulfonylamino)cyclohexanecarboxylate; hydrolysis; oxidation; intermediates | SHIONOGI & CO., LTD. (JP) | 2009-09-03 | — | — | US | disclosed |
| US-7547800-B2 | Process for trans-4-amino-1-cyclohexanecarboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20090043094-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2009-02-12 | — | — | US | disclosed |
| EP-2014285-A1 | NPYY5 antagonists | Shionogi&Co., Ltd. (JP) | 2009-01-14 | — | — | EP | disclosed |
| US-7459580-B2 | Process for trans-4-amino-1-cyclohexanecarboxilic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2008-12-02 | — | — | US | disclosed |
| US-20080039662-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| US-7314950-B2 | Process for producing trans-4-amino-1-cyclohexanecarboxilic acid derivative | SHIONOGI & CO., LTD. (JP) | 2008-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090043094-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXYLIC ACID DERIVATIVES | ACMSD, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, AADAT | MAPT 1721/4885NPY5R 4287/4885ALDH1A1 532/4885 |
| US-20100292500-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3367/4885NPY5R 1/4885ALDH1A1 4599/4885 |
| US-20110039802-A1 | NPY Y5 ANTAGONIST | NPY5R, NPY1R, NPY2R | MAPT 3683/4885NPY5R 1/4885ALDH1A1 4517/4885 |
| US-20080039662-A1 | PROCESS FOR TRANS-4-AMINO-1-CYCLOHEXANECARBOXILIC ACID DERIVATIVES | AADAT, ACMSD, AAAS | MAPT 1445/4885NPY5R 4619/4885ALDH1A1 679/4885 |
| US-20110060145-A1 | PROCESS FOR PRODUCTION OF COMPOUND HAVING ANTAGONISTIC ACTIVITY ON NPYY5 RECEPTOR, AND USEFUL CRYSTAL | NPY5R, NPY1R, NPY2R | MAPT 3951/4885NPY5R 1/4885ALDH1A1 4561/4885 |
| US-20090221817-A1 | Triethylamine was added dropwise to a solution of 2-methylpropane-2-sulfinyl chloride and methyl trans-4-amino-1-cyclohexane carboxylate p-toluenesulfonate in tetrahydrofuran solvent to obtain Methyl trans-4-(2-methylpropane-2-sulfonylamino)cyclohexanecarboxylate; hydrolysis; oxidation; intermediates | TST, ACMSD, PNMT | MAPT 3525/4885NPY5R 4668/4885ALDH1A1 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.